Advertisement

Surgery Versus Nonsurgical Therapy for Recurrent Adrenocortical Carcinoma

  • Zahraa Al-Hilli
  • Melanie L. Lyden
Chapter
Part of the Difficult Decisions in Surgery: An Evidence-Based Approach book series (DDSURGERY)

Abstract

Adrenocortical carcinoma is a rare endocrine neoplasm associated with poor prognosis. Complete surgical resection is the only potential cure for the disease. Unfortunately, a significant number of patients develop disease relapse and present with local or systemic recurrence. Close follow-up with regular clinical examination aided by radiological imaging and blood investigations is crucial for the early detection of recurrent disease. The best treatment options for recurrent disease remain unclear and these include surgery, chemotherapy, and radiotherapy, in addition to new and upcoming treatments. This chapter will focus on the treatment of recurrent ACC including a discussion of surgical and non-surgical therapy options.

Keywords

Adrenocortical carcinoma Recurrence Surgery Mitotane Chemotherapy Radiotherapy Radiofrequency ablation Treatment 

References

  1. 1.
    Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006;30:872–8.CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab. 2009;94:1853–78.CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.
    Wajchenberg BL, Albergaria Pereira MA, Medonca BB, Latronico AC, Campos Carneiro P, Alves VA, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer. 2000;88:711–36.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Allolio BFM. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006;91(6):2027–37.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Dackiw APB, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg. 2001;25:914–26.CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg. 2001;25:891–7.CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer. 2010;46:713–9.CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Koschker A-C, Fassnacht M, Hahner S, Weismann D, Allolio B. Adrenocortical carcinoma – improving patient care by establishing new structures. Exp Clin Endocrinol Diabetes. 2006;114:45–51.CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Hsing AW, Nam JM, Co Chien HT, McLaughlin JK, Fraumeni JF. Risk factors for adrenal cancer: an exploratory study. Int J Cancer. 1996;65:432–6.CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Hisada M, Garber JE, Fung CY, Fraumeni JF, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst. 1998;90:606–11.CrossRefPubMedCentralGoogle Scholar
  11. 11.
    Fassnacht M, Libé R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol. 2011;7:323–35.CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    McFarlane D. Cancer of the adrenal cortex; the natural history, pronosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl. 1958;23:155–86.Google Scholar
  13. 13.
    Sullivan M, Boileau MHC. Adrenal cortical carcinoma. J Urol. 1978;120:660–5.CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    DeLellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. Lyon: IARC; 2004.Google Scholar
  15. 15.
    Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, et al. Limited prognostic value of the 2004 international union against cancer staging classification for adrenocortical carcinoma. Cancer. 2009;115:243–50.CrossRefPubMedCentralPubMedGoogle Scholar
  16. 16.
    Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery. 1992;112:963–70. Discussion 970–1.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Stojadinovic A, Ghossein RA, Hoos A, Nissan A, Marshall D, Dudas M, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol. 2002;20:941–50.CrossRefPubMedCentralPubMedGoogle Scholar
  18. 18.
    Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P, Carbone G, et al. The italian registry for adrenal cortical carcinoma: analysis of a multiinstitutional series of 129 patients. Surgery. 1996;119:161–70.CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Linos D, Vassilopoulos P, Papadimitriou J, Tountas K. The surgical management of adrenal cortical carcinoma. Int Surg. 1986;71(2):104–6.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Decker R, Kuehner M. Adrenocortical carcinoma. Am Surg. 1991;57(8):502–13.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Jensen C. Recurrent or metastatic disease in select patients with adrenocortical carcinoma adrenocortical. Arch Surg. 1991;126:457–61.CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Van Aalderen W, Van Seters AP, Backer ET, Chang PC, Van Krieken JHJM, Moolenaar AJ. A case of recurrent adrenocortical carcinoma, with observations on long-term o,p’-DDD therapy and complications. Neth J Med. 1992;41:161–70.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Ahlman H, Jansson S, Wangberg B, Tisell L, Schersten T, Hansson G, et al. Adrenocortical carcinoma – diagnostic and therapeutical implications. Eur J Surg. 1993;159(3):149–58.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer. 1994;69:947–51.CrossRefPubMedCentralPubMedGoogle Scholar
  25. 25.
    Sakamoto K, Ariyoshi A, Okazaki M. Metastatic adrenocortical carcinoma treated by repeated resection: a case report of long-term survival over 18 years. Int J Urol. 1995;2:50–2.CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Bellantone R, Ferrante A, Boscherini M, Lombardi CP, Crucitti P, Crucitti F, et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery. 1997;122:1212–8.CrossRefPubMedCentralPubMedGoogle Scholar
  27. 27.
    Khorram-Manesh A, Ahlman H, Jansson S, Wängberg B, Nilsson O, Jakobsson CE, et al. Adrenocortical carcimona: surgery and mitotane for treatment and steroid profiles for follow-up. World J Surg. 1998;22:605–12.CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol. 1999;6:719–26.CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    Seki M, Nomura K, Hirohara D, Kanazawa M, Sawada T, Takasaki K, et al. Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma. Endocr Relat Cancer. 1999;6(4):529–33.CrossRefPubMedCentralPubMedGoogle Scholar
  30. 30.
    Langer P, Bartsch D, Moebius E, Rothmund M, Nies C. Adrenocortical carcinoma – our experience with 11 cases. Langenbeck’s Arch Surg. 2000;385:393–7.CrossRefGoogle Scholar
  31. 31.
    Ilias I, Alevizaki M, Philippou G, Anastasiou E, Souvatzoglou A. Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane. J Endocrinol Investig. 2001;24:532–5.CrossRefGoogle Scholar
  32. 32.
    Fujii Y, Kageyama Y, Kawakami S, Masuda H, Arisawa C, Akamatsu H, et al. Successful long-term disease-free survival following multimodal treatments in a patient with a repeatedly recurrent refractory adrenal cortical carcinoma. Int J Urol. 2003;10(8):445.CrossRefPubMedCentralPubMedGoogle Scholar
  33. 33.
    Tauchmanovà L, Colao A, Marzano LA, Sparano L, Camera L, Rossi A, et al. Andrenocortical carcinomas: twelve-year prospective experience. World J Surg. 2004;28:896–903.CrossRefPubMedCentralPubMedGoogle Scholar
  34. 34.
    Matsumoto K, Egawa S, Satoh T, Okuno N, Kaseda S, Baba S. Thoracoscopic transdiaphragmatic adrenalectomy for isolated locally recurrent adrenal carcinoma. Int J Urol. 2005;12:1055–7.CrossRefPubMedCentralPubMedGoogle Scholar
  35. 35.
    Palazzo FF, Sebag F, Sierra M, Ippolito G, Souteyrand P, Henry JF. Long-term outcome following laparoscopic adrenalectomy for large solid adrenal cortex tumors. World J Surg. 2006;30:893–8.CrossRefPubMedCentralPubMedGoogle Scholar
  36. 36.
    Schlamp A, Hallfeldt K, Mueller-Lisse U, Pfluger T, Reincke M. Recurrent adrenocortical carcinoma after laparoscopic resection. Nat Clin Pract Endocrinol Metab. 2007;3:191–5.CrossRefPubMedCentralPubMedGoogle Scholar
  37. 37.
    Tan CT, Meyer-Rochow GY, Sywak MS, Delbridge LW, Sidhu SB. Reoperative adrenal surgery: lessons learnt. ANZ J Surg. 2009;79:371–7.CrossRefPubMedCentralPubMedGoogle Scholar
  38. 38.
    Sabolch A, Feng M, Griffith K, Hammer G, Doherty G, Ben-Josef E. Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int J Radiat Oncol Biol Phys. 2011;80:1477–84.CrossRefPubMedCentralPubMedGoogle Scholar
  39. 39.
    Datrice NM, Langan RC, Ripley RT, Kemp CD, Steinberg SM, Wood BJ, et al. Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol. 2012;105:709–13.CrossRefPubMedCentralPubMedGoogle Scholar
  40. 40.
    Dy BM, Wise KB, Richards ML, Young WF, Grant CS, Bible KC, et al. Operative intervention for recurrent adrenocortical cancer. Surgery. 2013;154:1292–9.CrossRefPubMedCentralPubMedGoogle Scholar
  41. 41.
    Erdogan I, Deutschbein T, Jurowich C, Kroiss M, Ronchi C, Quinkler M, et al. The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:181–91.CrossRefPubMedCentralPubMedGoogle Scholar
  42. 42.
    Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356:2372–80.CrossRefPubMedCentralPubMedGoogle Scholar
  43. 43.
    Saunders BD, Doherty GM. Laparoscopic adrenalectomy for malignant disease. Lancet Oncol. 2004;5:718–26.CrossRefPubMedCentralPubMedGoogle Scholar
  44. 44.
    Shen WT, Lim RC, Siperstein AE, Clark OH, Schecter WP, Hunt TK, et al. Laparoscopic vs open adrenalectomy for the treatment of primary hyperaldosteronism. Arch Surg. 1999;134:628–31.CrossRefPubMedCentralPubMedGoogle Scholar
  45. 45.
    Cobb WS, Kercher KW, Sing RF, Heniford BT. Laparoscopic adrenalectomy for malignancy. Am J Surg. 2005;189(4):405–11.CrossRefPubMedCentralPubMedGoogle Scholar
  46. 46.
    Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005;6:386–94.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Kopf D, Goretzki PE, Lehnert H. Clinical management of malignant adrenal tumors. J Cancer Res Clin Oncol. 2001;127:143–55.CrossRefPubMedCentralPubMedGoogle Scholar
  48. 48.
    Terzolo M, Pia A, Berruti A, Osella G, Alì A, Carbone V, et al. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab. 2000;85:2234–8.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Faggiano A, Leboulleux S, Young J, Schlumberger M, Baudin E. Rapidly progressing high o,p’DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. Clin Endocrinol. 2006;64:110–3.CrossRefGoogle Scholar
  50. 50.
    Schteingart DE. Conventional and novel strategies in the treatment of adrenocortical cancer. Braz J Med Biol Res. 2000;33:1197–200.CrossRefPubMedCentralPubMedGoogle Scholar
  51. 51.
    Berruti A, Terzolo M, Sperone P, Pia A, Della Casa S, Gross DJ, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer. 2005;12:657–66.CrossRefPubMedCentralPubMedGoogle Scholar
  52. 52.
    Khan TS, Imam H, Juhlin C, Skogseid B, Gröndal S, Tibblin S, et al. Streptozocin and o,p’DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol. 2000;11:1281–7.CrossRefPubMedCentralPubMedGoogle Scholar
  53. 53.
    Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366:2189–97.CrossRefPubMedCentralPubMedGoogle Scholar
  54. 54.
    Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M, et al. Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii131–8.CrossRefPubMedCentralPubMedGoogle Scholar
  55. 55.
    Kornely E, Schlaghecke R. Complete remission of metastasized adrenocortical carcinoma under o,p’-DDD. Exp Clin Endocrinol. 1994;102:50–3.CrossRefPubMedCentralPubMedGoogle Scholar
  56. 56.
    Polat B, Fassnacht M, Pfreundner L, Guckenberger M, Bratengeier K, Johanssen S, et al. Radiotherapy in adrenocortical carcinoma. Cancer. 2009;115:2816–23.CrossRefPubMedCentralPubMedGoogle Scholar
  57. 57.
    Wood BJ, Abraham J, Hvizda JL, Alexander HR, Fojo T. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer. 2003;97:554–60.CrossRefPubMedCentralPubMedGoogle Scholar
  58. 58.
    Venkatesan AM, Locklin J, Dupuy DE, Wood BJ. Percutaneous ablation of adrenal Tumors. Tech Vasc Interv Radiol. 2010;13:89–99.CrossRefPubMedCentralPubMedGoogle Scholar
  59. 59.
    Beland MD, Mayo-Smith WW. Ablation of adrenal neoplasms. Abdom Imaging. 2009;34:588–92.CrossRefPubMedCentralPubMedGoogle Scholar
  60. 60.
    Atwell TD, Wass CT, Charboneau JW, Callstrom MR, Farrell MA, Sengupta S. Malignant hypertension during cryoablation of an adrenal gland tumor. J Vasc Interv Radiol. 2006;17:573–5.CrossRefPubMedCentralPubMedGoogle Scholar
  61. 61.
    Xiao YY, Tian JL, Li JK, Yang L, Zhang JS. CT-guided percutaneous chemical ablation of adrenal neoplasms. Am J Roentgenol. 2008;190:105–10.CrossRefGoogle Scholar
  62. 62.
    Li SH, Huang CH, Ko SF, Chou FF, Huang SC. Extended survival in a patient with recurrent and metastatic adrenal cortical carcinoma by aggressive transarterial embolization – a case report. J Surg Oncol. 2005;90:101–5.CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of General SurgeryCleveland ClinicClevelandUSA
  2. 2.Department of SurgeryMayo Clinic HospitalRochesterUSA

Personalised recommendations